Safety and Feasibility of Immuno-OCT

Conditions:   Colon Carcinoma;   Barrett Esophagus;   Gastrointestinal Dysplasia Intervention:   Drug: Bevacizumab-800CW Sponsor:   University Medical Center Groningen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials